Powered by

Disarm Therapeutics Expands Scientific Advisory Board with Experts in Neurology, Neuropathy, and Axonal Degeneration

Mar 06, 2018 - PR Newswire

 Disarm Therapeutics, a biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration, a central driver of neurological disease, today announced new Scientific Advisory Board (SAB) members. With deep experience across a range of neurological and neurodegenerative diseases, these advisors will lend their experience and insights to guide the company's research and translational strategy.

Ahmet Hoke, MD, PhD, is a professor of neurology an...